Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE

被引:94
|
作者
Yu, Philipp
Wellmann, Ute
Kunder, Sandra
Quintanilia-Martinez, Leticia
Jennen, Luise
Dear, Neil
Amann, Erstin
Bauer, Stefan
Winkler, Thomas H.
Wagner, Hermann
机构
[1] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany
[2] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, D-91054 Erlangen, Germany
[3] GSF, Inst Pathol, Natl Res Ctr Environm & Hlth, D-85764 Neuherberg, Germany
[4] Univ Sheffield, Div Clin Sci, Royal Hallamshire Hosp, Sheffield S10 2RX, S Yorkshire, England
[5] Univ Erlangen Nurnberg, Inst Pathol, Div Nephropathol, D-91054 Erlangen, Germany
[6] Univ Marburg, Inst Immunol, D-35037 Marburg, Germany
关键词
autoimmunity; B cells; innate immunity; systemic lupus erythematosus;
D O I
10.1093/intimm/dxl067
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The generation of anti-DNA auto-antibodies is characteristic for the human autoimmune condition systemic lupus erythematosus (SLE) and its animal models. However, the contribution of the toll-like receptor (TLR) system of innate immunity receptors and, in particular, TLR9 to this B cell-mediated autoimmune process remains controversial. Here we report that in a novel murine model of SLE, based on hyper-reactive B cell activation mediated by mutant phospholipase Cg2, the genetic deficiency of TLR9 does not protect from spontaneous anti-DNA auto-antibody formation and glomerulonephritis. On the contrary, disease induction is aggravated and additional nucleolar antibody specificity develops in autoimmune TLR9-deficient mice. In vitro studies demonstrate that, in autoimmune-prone mice, dual signaling via the B cell receptor and non-CpG DNA results in synergistic B cell activation in a TLR9-independent manner. These results suggest that engagement of a TLR9-independent DNA activation pathway may promote autoimmunity, while TLR9 signaling can ameliorate SLE-like immune pathology in vivo.
引用
收藏
页码:1211 / 1219
页数:9
相关论文
共 50 条
  • [1] Toll-Like Receptor 9 Deficiency Breaks Tolerance to RNA-Associated Antigens and Up-Regulates Toll-Like Receptor 7 Protein in Sle1 Mice
    Celhar, Teja
    Yasuga, Hiroko
    Lee, Hui Yin
    Zharkova, Olga
    Tripathi, Shubhita
    Thornhill, Susannah I.
    Lu, Hao K.
    Au, Bijin
    Lim, Lina H. K.
    Thamboo, Thomas P.
    Akira, Shizuo
    Wakeland, Edward K.
    Connolly, John E.
    Fairhurst, Anna-Marie
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (10) : 1597 - 1609
  • [2] Synthesis and immunological activities of novel agonists of toll-like receptor 9
    Struthers, Mary
    Bett, Andrew J.
    Wisniewski, Thomas
    Dubey, Sheri A.
    Precopio, Melissa
    Jiang, Weiwen
    Sun, Zhenhua
    Wang, Hao
    Nowak, Ireneusz
    Putta, Mallikarjuna R.
    Yu, Dong
    Tang, Jimmy X.
    Kandimalla, Ekambar R.
    Agrawal, Sudhir
    Casimiro, Danilo R.
    CELLULAR IMMUNOLOGY, 2010, 263 (01) : 105 - 113
  • [3] Targeting Toll-Like Receptors for Treatment of SLE
    Horton, Christopher G.
    Pan, Zi-jian
    Farris, A. Darise
    MEDIATORS OF INFLAMMATION, 2010, 2010
  • [4] Toll-Like Receptor 9 Agonists in Cancer
    Karapetyan, Lilit
    Luke, Jason J.
    Davar, Diwakar
    ONCOTARGETS AND THERAPY, 2020, 13 : 10039 - 10060
  • [5] Toll-like receptor 9 in breast cancer
    Sandholm, Jouko
    Selander, Katri S.
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [6] Modulating Toll-like Receptor 7 and 9 Responses as Therapy for Allergy and Autoimmunity
    Damir Matesic
    Aleksander Lenert
    Petar Lenert
    Current Allergy and Asthma Reports, 2012, 12 : 8 - 17
  • [7] Modulating Toll-like Receptor 7 and 9 Responses as Therapy for Allergy and Autoimmunity
    Matesic, Damir
    Lenert, Aleksander
    Lenert, Petar
    CURRENT ALLERGY AND ASTHMA REPORTS, 2012, 12 (01) : 8 - 17
  • [8] Toll-like receptor 5 and Toll-like receptor 9 single nucleotide polymorphisms and risk of systemic lupus erythematosus and nephritis in Egyptian patients
    Gharbia, Ola Mohammad
    Bassiouni, Sherine Abdel Rahman
    Zaki, Maysaa El Sayed
    El-Beah, Shimaa Mohsen
    El-Desoky, Manal Mohamed
    Elmansoury, Eman Adel
    Abdelsalam, Mostafa
    EGYPTIAN RHEUMATOLOGY AND REHABILITATION, 2021, 48 (01)
  • [9] Toll-like receptors involved in the response to microbial pathogens: Development of agonists for toll-like receptor 9
    Schetter, C
    Vollmer, J
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (02) : 204 - 210
  • [10] Toll-like receptor 9 agonists as cancer therapeutics
    Holtick, Udo
    Scheulen, Max E.
    von Bergwelt-Baildon, Michael S.
    Weihrauch, Martin R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (03) : 361 - 372